Curriculum îracking		APPRO	NED I	12/11/12 1:05 PM RECEIVED	
	The Univers	ity Of Tole	edo	JAN 16 2013	
	New Graduate	Course Propos	al	COLLEGE OF GRADUATE STUDIES	
	* denotes re	equired fields			
1. College*: College of Ph	armacy 🛟				
Department*: Pharmac	Department*: Pharmacology				
2. Contact Person*: Williar william.messer@utoledo.edu		-1958 (xxx - xxxx)	Email:		
3. Alpha/Numeric Code (S	Subject area - number)*: P	HCL - 7	7200		
4. Proposed title*: Experim	ental Therape				
Proposed effective term	*: 201410 (e.	g. 201140 for 2011 Fa	all)		
5. Is the course cross-listed with another academic unit? O S Yes No					
	emic unit (signature and titl	e)			
Is the course offered at	more than one level?		⊙ Yes	⊙ No	
new, complete the New	e course proposal form mus <u>Undergraduate Course Pro</u> se Modification Proposal.				
6. Credit hours*:	Fixed: 3	or	Variable:		
to					
7. Delivery Mode:	Primary*	Secondary	Terti	ary	
a. Activity Type *	(Lecture +)	Web Assisted Instru	•)	SelectType 🛊	
b. Minimum Credit Hours *	3		·····		
Maximum Credit Hours *	3				
c. Weekly Contact	3				

8.	Hours *									
0.	Terms offered:	🗍 Fall	⊠ Spring	□ Summe	r					
	Years offered:	⊙ Every	v Year	() Alternate	Ye	ears				
9. A	are students permi	itted to	register	for more th	an	one secti	on dui	ing a term?	③ No	O Yes
N	lay the courses be	e repea	ted for cr	edit? 💮 No		O Yes		Maximum Hours		
10	Grading System*:	O Pass Crec O Grac O Aud	sing Grad lit/No Cr	ling (A-F, F le/No Credi redit (A-F, PR, I)	t (1					

11. Prerequisites (must be taken **before**): i.e. C or higher in (BIOE 4500 or BIOE 5500) and C or higher in MATH 4200

B- or higher in PHCL 5100 or PHCL 7100		
0		
PIN (Permisson From Instructor) Co-requisites (must be taken together):	PDP (Permission From Department)	
Co-requisites (must be taken together):		

12.

Catalog Description* (75 words Maximum)

The course will expand upon material covered in Experimental Therapeutics I and focus on the drug development process. Practical applications include the design of in vitro and in vivo screens for drug activity, improvement of pharmacokinetic properties and integration of medicinal chemistry with pharmacology in a drug development paradigm.

https://curriculumtracking.utoledo.edu/GradNewCourse.aspx?Mode=View&ID=PHCL7200

8.	Hours *									
0.	Terms offered:	⊡ Fall	⊠ Spring	口 Sum	mer					
	Years offered:	④ Every	Year) Alterna	ite Y	ears				
9. A	re students permi	tted to	register	for more	than	one sect	tion dur	ing a term?	④ No) Yes
N	fay the courses be	e repeat	ed for cr		🕑 No	〇 Yes		Maximum Hours		
10	Grading System*:	O Passi O Credi O Grado	ng Grad it/No Cr e Only (t Only	e/No Cr edit	edit (/NC, PR, [A-C, NC	ŕ			

11. Prerequisites (must be taken **before**): i.e. C or higher in (BIOE 4500 or BIOE 5500) and C or higher in MATH 4200

<u>O</u>	<u> </u>
PIN (Permisson From Instructor)	PDP (Permission From Department)
Co-requisites (must be taken together):	

Catalog Description* (75 words Maximum)

The course will expand upon material covered in Experimental Therapeutics I and focus on the drug development process. Practical applications include the design of in vitro and in vivo screens for drug activity, improvement of pharmacokinetic properties and integration of medicinal chemistry with pharmacology in a drug development paradigm.

https://curriculumtracking.utoledo.edu/GradNewCourse.aspx?Mode=View&ID=PHCL7200

13. Attach a syllabus and an electronic copy of a complete outline of the major topics covered. Click <u>here for template</u>.

File Type	View File
Syllabus	<u>View</u>

Course Approval:

Department Curriculum Authority:

Department Chairperson:

College Curriculum Authority or Chair:

College Dean:

Graduate Council:

Dean of Graduate Studies:

Office of the Provost :

Enland	
Ezdihar Hassoun	Date 2012/11/05
WELLAM _ L	
William S. Messer, Jr.	Date 2012/11/05
winnann 5. Messel, ji.	
	Date 2012/12/04
Surya Nauli	L.
Wayna Haas	Date 2012/12/04
Wayne Hoss auguse from	
- Alton	- Date 2-5-20/3
FRIM	
-AAAAA	Date 2-5-2013
- Fl/Spon S	
P.	- Date

Administrative Use Only

Effective Date:	(YYYY/MM/DD)
CIP Code:	
Subsidy Taxonomy:	
Program Code:	
Instructional Level:	

https://curriculum tracking.utoledo.edu/GradNewCourse.aspx?Mode=View&ID=PHCL7200

The University of Toledo • 2801 W. Bancroft • Toledo, OH 43606-3390 • 1.800.586.5336 © 2006-2007 The University of Toledo. All rights reserved. • Send all feedback / comments to <u>webMaster</u>

> , 4

.

The University of Toledo • 2801 W. Bancroft • Toledo, OH 43606-3390 • 1.800.586.5336 © 2006-2007 The University of Toledo. All rights reserved. • Send all feedback / comments to webMaster

> . . - ..

https://curriculum tracking.utoledo.edu/GradNewCourse.aspx?Mode=View&ID=PHCL7200

.

The following requirements will be differentiated for courses that are co-listed for Masters (5000 or 6000) and Ph.D. (7000 or 8000) levels:

Masters students will need to complete successfully all course requirements as indicated in the syllabus. They should be able to achieve and demonstrate comprehensive understanding of course topics through class discussion, assignments, quizzes and exams.

To complete the course requirements, Ph.D. students will need to demonstrate an extended expertise in the course topics. They also should demonstrate independent scholarly activity and creativity to the class instructor. The ability of the Ph.D. level students to synthesize scientific data/information, develop original ideas/hypotheses and Formulate independent research studies/proposals will be evaluated through additional assignments and readings, or by demonstrating leadership roles in class discussion or other collaborative settings."

PHCL 7200 Experimental Therapeutics II Course Syllabus Spring 2014

Instructor(s):Dr. William S. Messer, Jr.Office/Office Hours:HEB 274C, M-W, 3:00 to 5:00 p.m.Phone:419-383-1958Email:william.messer@utoledo.edu

Class Time and Location: MWF, 8:00 to 8:50 a.m.

Primary Communication Method: Lecture

Course Description: The course will expand upon material covered in Experimental Therapeutics I and focus on the drug development process. Practical applications include the design of in vitro and in vivo screens for drug activity, improvement of pharmacokinetic properties and integration of medicinal chemistry with pharmacology in a drug development paradigm.

Course Objectives:

- 1) By the end of the semester, students will be able to outline the steps involved in the drug development process and identify critical issues that must be addressed at each step.
- 2) Students will be able to identify suitable targets for drug development and identify primary and secondary assays for evaluating drug activity.
- 3) Students will also be able to develop strategies for modifying lead compounds to enhance pharmacokinetic properties.
- 4) Students will be able to apply advanced principles of pharmacology to the development of new therapeutics by writing a research paper that describes in detail a comprehensive drug development project.

Required/Recommended Texts: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition, edited by Laurence L. Brunton, Bruce A. Chabner and Björn C. Knollmann, The McGraw-Hill Companies, Inc., Chicago, IL, 2011. ISBN 978-0-07-162442-8

Course Policies:

General- Students are expected to attend classes, although attendance is not routinely taken. In the event of absence from class, students will be responsible for completing all assignments.

Exams- Two exams will be given during the semester. Each exam will be worth 100 points.

Research paper- A research paper (worth 100 points) will be due by Friday of the 15th week of class.

Make-Up Exams- Make-up examinations will be given only to those students who obtain an excused absence from the instructor prior to the examination or during the first class session following the

examination. Late excuses will not be accepted. Make-up examinations will be scheduled only during the final examination period and may be administered in essay format.

Academic Dishonesty Statement- Cheating on exams will not be tolerated. Students guilty of cheating will be prosecuted according to College and University policies.

Students with Disabilities Statement- Students with disabilities who believe they may need academic accommodations are encouraged to speak with me after class and to contact the Office of Accessibility (Rocket Hall 1820; 419.530.4981; officeofaccessibility@utoledo.edu) as soon as possible for more information and/or to initiate the process for accessing academic accommodations.

Course Grade: Final course grades will be determined as a percentage of the total accumulated points of the two examinations administered during the semester and the research paper (300 possible points).

Letter Grade	Numerical average (%)	Quality points
А	90.0-100	4.0
A-	88.5-89.9	3.67
B+	86.5-88.4	3.33
В	80.0-86.4	3.0
B-	78.5-79.9	2.67
C+	76.5-78.4	2.33
C	68.5-76.4	2.0
D+	66.5-68.4	1.33
D	60.0-66.4	1.0
D-	58.5-59.9	0.67
F	0-58.4	0

Grading Scale: The following grading scale will be used:

Lecture Topics and Exams Schedule:

Week 1-3

Week 4In vitro testingWeek 5In vivo testingWeek 6In silico model designWeek 7Proteomics/genomics in drug designWeek 8Physical properties in drug design (Exam I)Week 9Structure activity relationship

Drug discovery process

examination. Late excuses will not be accepted. Make-up examinations will be scheduled only during the final examination period and may be administered in essay format.

Academic Dishonesty Statement- Cheating on exams will not be tolerated. Students guilty of cheating will be prosecuted according to College and University policies.

Students with Disabilities Statement- Students with disabilities who believe they may need academic accommodations are encouraged to speak with me after class and to contact the Office of Accessibility (Rocket Hall 1820; 419.530.4981; officeofaccessibility@utoledo.edu) as soon as possible for more information and/or to initiate the process for accessing academic accommodations.

Course Grade: Final course grades will be determined as a percentage of the total accumulated points of the two examinations administered during the semester and the research paper (300 possible points).

Letter Grade	Numerical average (%)	Quality points
А	90.0-100	4.0
A-	88.5-89.9	3.67
B+	86.5-88.4	3.33
B	80.0-86.4	3.0
В-	78.5-79.9	2.67
C+	76.5-78.4	2.33
С	68.5-76.4	2.0
D+	66.5-68.4	1.33
D	60.0-66.4	1.0
D-	58.5-59.9	0.67
F	0-58.4	0

Grading Scale: The following grading scale will be used:

Lecture Topics and Exams Schedule:

Week 1-3

Week 4	In vitro testing
Week 5	In vivo testing
Week 6	In silico model design
Week 7	Proteomics/genomics in drug design
Week 8	Physical properties in drug design (Exam I)
Week 9	Structure activity relationship

Drug discovery process

- Week 10 Efficacy vs potency vs therapeutic index
- Week 11 FDA and drug development process
- Week 12 Target selection in drug discovery and development
- Week 13 Sources of new drugs
- Week 14 Medicinal chemistry vs combinatorial chemistry
- Week 15 Design a drug development project